Therapeutic banner
Therapeutic banner

Primary Hyperoxaluria Type 1 (PH1)

View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to PH1.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.

Explore Therapeutic Areas

Publications

View More Arrow

Primary Hyperoxaluria Type 1 (PH1)

Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children

Genetics in Medicine

Author(s)

David J Sas, Daniella Magen, Wesley Hayes, et al

December 2021

Primary Hyperoxaluria Type 1 (PH1)

Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review Study

Frontiers in Medicine

Author(s)

Xiangling Wang, David Danese, Thomas Brown, et al

September 2021

Primary Hyperoxaluria Type 1 (PH1)

Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial

Clinical Journal of the American Society of Nephrology

Author(s)

Yaacov Frishberg, Georges Deschênes, Jaap W Groothoff, et al

May 2021

Primary Hyperoxaluria Type 1 (PH1)

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

New England Journal of Medicine

Author(s)

Sander F Garrelfs, Yaacov Frishberg, Sally A Hulton, et al

April 2021

Primary Hyperoxaluria Type 1 (PH1)

Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria

eLife

Author(s)

Tracy L McGregor, Karen A Hunt, Elaine Yee, et al

March 2020